Gilead Sciences, Inc. (LON:0QYQ)

Market Cap	96.74B
Revenue (ttm)	22.24B
Net Income (ttm)	4.62B
Shares Out	n/a
EPS (ttm)	3.66
PE Ratio	20.95
Forward PE	12.86
Dividend	2.39 (2.19%)
Ex-Dividend Date	Jun 13, 2025

Volume	9,237
Average Volume	28,593
Open	110.30
Previous Close	108.60
Day's Range	107.39 - 111.84
52-Week Range	64.33 - 121.38
Beta	0.31
RSI	43.53
Earnings Date	Aug 1, 2025

About Gilead Sciences

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy p...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1987
• Employees: 17,600
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0QYQ

Financial Performance

In 2024, Gilead Sciences's revenue was $28.75 billion, an increase of 6.04% compared to the previous year's $27.12 billion. Earnings were $480.00 million, a decrease of -91.53%.

Financial numbers in USD